Clinical trial · Interventional
Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer
Intensive Combination Chemotherapy With Autologous Bone Marrow Rescue for Metastatic Breast Cancer After Intitial Cytoreduction With Standard Agents: A Phase II Study
NCT00584766CI-TRIAL-00018079completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the therapeutic efficacy of high-dose cyclophosphamide and BCNU with autologous bone marrow transplantation after initial tumor cytoreduction for patients with receptor-negative metastatic breast carcinoma and to determine the optimal timing of CyBCNU-ABMT after initial development of metastatic breast carcinoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| High-dose chemotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Procedure: High-dose chemotherapy
Primary outcomes (1)
- measure
- Quality of maximal response; time to initial disease progression; and overall survival
- timeFrame
- undetermined
Secondary outcomes (1)
- measure
- to determine the optimal timing of CyBCNU-ABMT after initial development of metastatic breast cancer
- timeFrame
- undetermined
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * breast carcinoma at first clinical evidence of metastatic disease * must have measurable disease by physical exam, x-ray, or scan * Age \< or equal to 55 * performance status 0-2 Exclusion Criteria: * can't have had more than one prior chemotherapy regimen * can't have had concurrent hormonal therapy * no brain metastases * no previous pelvic radiation * no history of another malignancy
References
Publications (0)
Data not yet available
No reference posted for this study.